Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:e106
Published online before print August 23, 2007, doi: 10.1161/STROKEAHA.107.492843
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/10/e106    most recent
STROKEAHA.107.492843v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castilla-Guerra, L.
Right arrow Articles by del Carmen Fernandez-Moreno, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castilla-Guerra, L.
Right arrow Articles by del Carmen Fernandez-Moreno, M.

(Stroke. 2007;38:e106.)
© 2007 American Heart Association, Inc.


Letters to the Editor

Stroke in Diabetic Patients: Is It Really a Macrovascular Complication?

Luis Castilla-Guerra, MD, PhD

Department of Internal Medicine, Hospital de la Merced, Osuna, Seville, Spain

Maria del Carmen Fernandez-Moreno, MD

Department of Neurology, Hospital Universitario de Valme, Seville, Spain

To the Editor:

We have read with interest the article by Wilcox et al,1 in which they demonstrated the positive effect of pioglitazone on stroke recurrence in patients with type 2 diabetes mellitus (DM). However, we would like to stress a particular concern regarding a basic concept in the difficult question of DM and stroke. In this study, as in other previous studies, stroke is considered a macrovascular event in diabetic patients, but is this statement true? Traditionally, retinopathy, neuropathy, and nephropathy have been designated microvascular complications of DM, and stroke, myocardial infarction and gangrene are termed macrovascular complications.2 However, we think it is time to change this commonly accepted concept.

The pathophysiology of cerebrovascular disease in patients with DM is not fully characterized, but both large and small blood vessels seem to be affected. Thus, the etiology of strokes in diabetics is frequently microvascular disease from fibrinoid necrosis, which causes small subcortical infarcts or lacunar strokes.3

Different studies have suggested that, though there is no doubt that diabetes is an important risk factor for ischemic stroke overall, the increase in relative risk must be similar for all subtypes of ischemic strokes. Most of the previous population-based studies have not suggested any hint of a particular association between DM and any subtype of ischemic stroke. Similar results have been obtained in a systematic review of all relevant hospital-based and population-based studies.3,4 Furthermore, in the Atherosclerosis Risk in Communities Study,5 a prospective study of 14 448 men and women, even the authors observed a positive association between lacunar strokes and diabetes, with a population-attributable fraction for DM of 26.3% for lacunar versus 11.3% for nonlacunar stroke. Finally, in a recent prospective study among 116 316 female registered nurses in a 24-year follow-up study, researchers found that the risk for large-artery infarction and lacunar stroke were similar in diabetic women.6

In conclusion, it may be too simplistic to consider stroke a macrovascular complication of DM, as long as both microvascular and macrovascular factors operate simultaneously and intensively in diabetics’ brain vascular damage. Given the significant public health impact of stroke and diabetes, further studies are required to identify all risk factors for vascular diabetic disease and apply appropriate preventive strategies.

Acknowledgments

Disclosures

None.

References

1. Wilcox R, Bouser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROACTIVE. Stroke. 2007; 38: 865–873.[Abstract/Free Full Text]

2. Unger RH, Foster DW. Diabetes mellitus. In Wilson JD, Foster DW, Kronembenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 1998; 973–1059.

3. Rothwell PM. Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. Cerebrovasc Dis. 2005; 20: 24–34.[CrossRef][Medline] [Order article via Infotrieve]

4. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of different risk profiles between lacunar and nonlacunar infarcts. Stroke. 2005; 366: 29–36.

5. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH, Folsom AR. Risk factors for ischemic stroke subtypes. Stroke. 2006; 37: 2493–2502.[Abstract/Free Full Text]

6. Janghorbani M, Hu FB, Willett WC, Li TY, Manson JE, Logroscino G, Rexrode KM. Prospective study of type 1 and type 2 diabetes and risk of stroke subtype: the Nurses’ Health Study. Diabetes Care. 2007; 30: 1730–1735.[Abstract/Free Full Text]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/10/e106    most recent
STROKEAHA.107.492843v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Castilla-Guerra, L.
Right arrow Articles by del Carmen Fernandez-Moreno, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castilla-Guerra, L.
Right arrow Articles by del Carmen Fernandez-Moreno, M.